Abstract
The authors reported on the results of their clinical investigations of KW-1070, a new aminoglycoside antibiotic.
1. The antibacterial activity of KW-1070 was compared to that of gentamicin (GM), amikacin (AMK) and netilmicin (NTL) in a total of 178 clinically isolated strains of S.aureus, S.faecalis, E.coli, Citrobacter, Klebsiella, Enterobacter, Serratsa, Proteus and P.aeruginosa.
Antibacterial activity of KW-1070 against E.coli, Enterobacter, Serratia, P.msrabilis, P.vulgaris and P.rettgeri was almost the same as that of AMK, while MIC of KW-1070 against S.aureus and P.aeruginosa was higher than that of GM, AMK and NTL.
2. KW-1070 was administered to a total of 14 patients, consisting of 10 cases of respiratory tract infections (RTI) and 4 cases of urinary tract infections (UTI).
The results obtained were good in 6 (60.0%) out of 10 RTI and in 3 (75.0%) out of 4 UTI cases.
No adverse reaction was observed.
